Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abiomed, Inc. stock logo
ABMD
Abiomed
$381.02
$380.55
$219.85
$381.99
$17.18B1.4611,028 shs258 shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$59.10
-2.4%
$61.94
$54.48
$94.93
$8.20B1.191.13 million shs1.81 million shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$76.85
+0.8%
$68.82
$55.30
$94.99
$3.66B0.39671,771 shs249,556 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$250.54
+0.3%
$271.10
$148.00
$310.00
$9.67B0.47453,066 shs233,847 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$17.06
-0.1%
$20.55
$15.75
$48.24
$1.14B1.481.48 million shs1.10 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00%0.00%0.00%0.00%0.00%
Globus Medical, Inc. stock logo
GMED
Globus Medical
+0.67%+3.97%+2.70%-16.01%-11.07%
Haemonetics Corporation stock logo
HAE
Haemonetics
-0.17%+3.73%+10.87%+22.74%-8.19%
Penumbra, Inc. stock logo
PEN
Penumbra
-0.66%-1.50%-2.74%-8.57%+41.79%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-0.93%-12.05%-15.53%-3.28%-56.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abiomed, Inc. stock logo
ABMD
Abiomed
1.5591 of 5 stars
0.00.00.04.30.61.71.9
Globus Medical, Inc. stock logo
GMED
Globus Medical
4.9581 of 5 stars
4.35.00.04.12.72.51.9
Haemonetics Corporation stock logo
HAE
Haemonetics
4.8604 of 5 stars
4.52.00.04.32.11.72.5
Penumbra, Inc. stock logo
PEN
Penumbra
4.7339 of 5 stars
3.43.00.03.73.42.51.9
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4.3068 of 5 stars
4.21.00.04.93.40.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00
N/AN/AN/A
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.62
Moderate Buy$94.0059.05% Upside
Haemonetics Corporation stock logo
HAE
Haemonetics
2.91
Moderate Buy$96.8025.97% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.4020.70% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.40
Hold$33.4395.90% Upside

Current Analyst Ratings Breakdown

Latest HAE, PEN, GMED, TNDM, and ABMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$87.00
6/25/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$24.00
6/10/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/27/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/27/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
5/22/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.00
5/20/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$100.00 ➝ $100.00
5/12/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$80.00 ➝ $68.00
5/9/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$100.00 ➝ $80.00
5/9/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$115.00 ➝ $105.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abiomed, Inc. stock logo
ABMD
Abiomed
$1.03B16.65$5.09 per share74.88$33.03 per share11.54
Globus Medical, Inc. stock logo
GMED
Globus Medical
$2.52B3.18$6.49 per share9.10$30.40 per share1.94
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.36B2.71$7.26 per share10.58$16.34 per share4.70
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B8.12$2.90 per share86.52$29.99 per share8.35
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$940.20M1.21N/AN/A$4.01 per share4.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abiomed, Inc. stock logo
ABMD
Abiomed
$136.51M$5.8265.4769.783.3324.84%14.77%13.32%N/A
Globus Medical, Inc. stock logo
GMED
Globus Medical
$102.98M$1.3444.1014.671.767.39%10.52%8.56%8/5/2025 (Estimated)
Haemonetics Corporation stock logo
HAE
Haemonetics
$167.68M$3.3123.2215.251.2312.32%26.37%9.22%8/14/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$1.06236.3650.012.233.41%11.14%8.40%7/29/2025 (Estimated)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%7/30/2025 (Estimated)

Latest HAE, PEN, GMED, TNDM, and ABMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.81N/AN/AN/A$327.37 millionN/A
5/8/2025Q1 2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.74$0.68-$0.06$0.54$629.74 million$598.12 million
5/8/2025Q4 2025
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.22$1.24+$0.02$1.17$329.38 million$330.60 million
4/30/2025Q1 2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 million
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/AN/A
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Corporation stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abiomed, Inc. stock logo
ABMD
Abiomed
N/A
7.93
7.17
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
4.45
2.72
Haemonetics Corporation stock logo
HAE
Haemonetics
1.12
1.62
0.99
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.30
3.68
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.99
2.30
1.81

Institutional Ownership

CompanyInstitutional Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
94.48%
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Corporation stock logo
HAE
Haemonetics
99.67%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
2.50%
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.51%
Haemonetics Corporation stock logo
HAE
Haemonetics
1.84%
Penumbra, Inc. stock logo
PEN
Penumbra
4.20%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abiomed, Inc. stock logo
ABMD
Abiomed
2,00345.09 million43.96 millionOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
5,300135.38 million110.32 millionOptionable
Haemonetics Corporation stock logo
HAE
Haemonetics
3,02348.04 million47.16 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50038.73 million37.10 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,65066.61 million65.34 millionOptionable

Recent News About These Companies

RSI Alert: Tandem Diabetes Care (TNDM) Now Oversold
TNDM - Tandem Diabetes Care Inc Key Metrics - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abiomed stock logo

Abiomed NASDAQ:ABMD

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Globus Medical stock logo

Globus Medical NYSE:GMED

$59.10 -1.47 (-2.43%)
Closing price 03:34 PM Eastern
Extended Trading
$59.10 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Haemonetics stock logo

Haemonetics NYSE:HAE

$76.84 +0.61 (+0.79%)
Closing price 03:44 PM Eastern
Extended Trading
$76.84 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Penumbra stock logo

Penumbra NYSE:PEN

$250.54 +0.80 (+0.32%)
Closing price 03:53 PM Eastern
Extended Trading
$250.54 0.00 (0.00%)
As of 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Tandem Diabetes Care stock logo

Tandem Diabetes Care NASDAQ:TNDM

$17.06 -0.02 (-0.09%)
Closing price 03:58 PM Eastern
Extended Trading
$16.72 -0.34 (-2.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.